Biogen Inc. (NASDAQ:BIIB) to Release Earnings on Tuesday

Biogen Inc. (NASDAQ:BIIB) is scheduled to be releasing its earnings data before the market opens on Tuesday, July 25th. Analysts expect Biogen to post earnings of $4.50 per share for the quarter.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Tuesday, April 25th. The biotechnology company reported $5.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.97 by $0.23. Biogen had a return on equity of 38.17% and a net margin of 30.17%. The company had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period in the prior year, the company earned $4.79 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, analysts expect Biogen to post $20.45 EPS for the current fiscal year and $22.66 EPS for the next fiscal year.

Shares of Biogen Inc. (NASDAQ BIIB) opened at 282.65 on Tuesday. The company has a market capitalization of $59.95 billion, a P/E ratio of 17.70 and a beta of 0.77. The firm has a 50 day moving average price of $259.24 and a 200 day moving average price of $274.78. Biogen Inc. has a one year low of $234.11 and a one year high of $307.76.

WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/07/18/biogen-inc-nasdaqbiib-to-release-earnings-on-tuesday.html.

Several research analysts have recently weighed in on the company. Vetr lowered Biogen from a “strong-buy” rating to a “buy” rating and set a $310.46 price objective for the company. in a research report on Tuesday, April 25th. Stifel Nicolaus lifted their price objective on Biogen from $265.00 to $280.00 and gave the stock a “hold” rating in a research report on Wednesday, April 26th. Credit Suisse Group set a $300.00 price objective on Biogen and gave the stock a “hold” rating in a research report on Friday. Leerink Swann reaffirmed a “market perform” rating on shares of Biogen in a research report on Thursday, June 22nd. Finally, Deutsche Bank AG started coverage on Biogen in a research report on Friday, June 23rd. They issued a “buy” rating and a $315.00 target price for the company. Thirteen equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. Biogen presently has an average rating of “Buy” and a consensus target price of $325.48.

In other Biogen news, VP Paul J. Clancy sold 9,892 shares of the business’s stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $290.00, for a total transaction of $2,868,680.00. Following the sale, the vice president now owns 10,813 shares of the company’s stock, valued at approximately $3,135,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brian S. Posner sold 1,084 shares of the business’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $256.31, for a total transaction of $277,840.04. Following the sale, the director now directly owns 6,330 shares in the company, valued at approximately $1,622,442.30. The disclosure for this sale can be found here. Insiders own 0.32% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Earnings History for Biogen (NASDAQ:BIIB)

What are top analysts saying about Biogen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biogen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit